ARTICLE | Company News

Sun licenses Merck's tildrakizumab

September 18, 2014 1:14 AM UTC

Merck & Co. Inc. (NYSE:MRK) granted Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) exclusive, worldwide rights to tildrakizumab ( MK-3222). The anti-IL-23 antibody is in two Phase III trials to treat chronic plaque psoriasis, with data expected in June 2015.

Merck will receive $80 million up front and is eligible for undisclosed regulatory and sales milestones as well as tiered royalties. Sun will fund Merck's ongoing clinical and regulatory development of tildrakizumab, and will assume full responsibility for further development and potential commercialization. ...